<DOC>
	<DOCNO>NCT01268098</DOCNO>
	<brief_summary>Use PTH ( 1-84 ) recombinant hormone 25 µg 50 µg dos treatment adult hypoparathyroidism . The use PTH ( 1-84 ) result decrease calcium vitamin D supplement .</brief_summary>
	<brief_title>Study Safety Efficacy rhPTH1-84 Fixed Doses 25 50 mcg Adults With Hypoparathyroidism ( RELAY )</brief_title>
	<detailed_description>Patients history Hypoparathyroidism randomize receive study drug 8 week , inject daily either thigh . During time monitor safety ( specifically calcium level blood urine ) . In addition , patient ' intake Vitamin D Calcium measure .</detailed_description>
	<mesh_term>Hypoparathyroidism</mesh_term>
	<criteria>Main 1 . Previously complete 24 week therapy 4 week followup REPLACE study 2 . With regard female patient : woman postmenopausal willing use two medically acceptable method contraception duration study pregnancy test conduct every scheduled office visit 3 . Total serum calcium ≤ ULN base local laboratory result prior randomization 4 . Serum 25 ( OH ) vitamin D ≤ 1.5 time ULN within approximately 8 week prior randomization Main 1 . Any disease condition , opinion investigator , high probability preclude patient complete study able appropriately comply study requirement 2 . Use raloxifene hydrochloride intravenous ( IV ) bisphosphonates since end participation REPLACE trial 3 . Chronic ( ie , ≥ 1 month exposure ) use systemic corticosteroid , oral bisphosphonates , calcitonin , fluoride tablet , cinacalcet hydrochloride 4 . Pregnant lactate woman 5 . Any condition would , investigator 's opinion consultation sponsor , preclude safe use PTH 6 . Use experimental drug NPSP558 within 3 month baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Hypoparathyroidism , rhPTH [ 1-84 ] , NPSP558</keyword>
</DOC>